Skip to main content
Erschienen in: American Journal of Clinical Dermatology 8/2003

01.08.2003 | Current Opinion

Peroxisome Proliferator-Activated Receptor (PPAR)-β as a Target for Wound Healing Drugs

What is Possible?

verfasst von: Nguan Soon Tan, Liliane Michalik, Beatrice Desvergne, Professor Walter Wahli

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 8/2003

Einloggen, um Zugang zu erhalten

Abstract

Peroxisome proliferator-activated receptor (PPAR) dysfunction has been implicated in the manifestation of many diseases and illnesses, ranging from obesity to cancer. Herein, we discuss the role of PPARβ, one of the three PPAR isotypes, during wound healing. While PPARβ expression is undetectable in unchallenged and healthy adult interfollicular mouse skin, it is robustly re-activated in stress situations, such as upon phorbol ester treatment, hair plucking and cutaneous wounding. The inflammatory reaction associated with a skin injury activates the keratinocytes at the edges of the wound. This activation involves PPARβ, whose expression and activity as transcription factor are up-regulated by pro-inflammatory signals. The re-activation of PPARβ influences three important properties of the activated keratinocytes that are vital for rapid wound closure, namely, survival, migration and differentiation. The anti-apoptotic and, thus, survival role of PPARβ is mediated by the up-regulation of expression of integrin-linked kinase and 3-phosphoinositide-dependent kinase-1. Both kinases are required for the full activation of the Akt1 survival cascade. Therefore, the up-regulation of PPARβ, early after injury, appears to be important to maintain a sufficient number of viable keratinocytes at the wound edge. At a later stage of wound repair, the stimulation of keratinocyte migration and differentiation by PPARβ is also likely to be important for the formation of a new epidermis at the wounded area. Consistent with these observations, the entire wound healing process is delayed in PPARβ +/− mice and wound closure is retarded by 2–3 days. The multiple roles of PPARβ in the complex keratinocyte response after injury and during skin repair certainly justify a further exploration of its potential as a target for wound healing drugs.
Literatur
1.
Zurück zum Zitat Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999 Apr 16; 97 (2): 161–3CrossRef Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999 Apr 16; 97 (2): 161–3CrossRef
2.
Zurück zum Zitat Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999 Oct; 20 (5): 649–88PubMedCrossRef Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999 Oct; 20 (5): 649–88PubMedCrossRef
3.
Zurück zum Zitat Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000 Mar 17; 448 (2): 121–38PubMedCrossRef Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000 Mar 17; 448 (2): 121–38PubMedCrossRef
4.
Zurück zum Zitat Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999 Jun; 103 (11): 1489–98PubMedCrossRef Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999 Jun; 103 (11): 1489–98PubMedCrossRef
5.
Zurück zum Zitat Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001 Jun; 169 (3): 453–9PubMedCrossRef Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001 Jun; 169 (3): 453–9PubMedCrossRef
6.
Zurück zum Zitat Devchand PR, Keller H, Peters JM, et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996 Nov 7; 384 (6604): 39–43PubMedCrossRef Devchand PR, Keller H, Peters JM, et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996 Nov 7; 384 (6604): 39–43PubMedCrossRef
7.
Zurück zum Zitat Rosen ED, Walkey CJ, Puigserver P, et al. Transcriptional regulation of adipogenesis. Genes Dev 2000 Jun 1; 14 (11): 1293–307PubMed Rosen ED, Walkey CJ, Puigserver P, et al. Transcriptional regulation of adipogenesis. Genes Dev 2000 Jun 1; 14 (11): 1293–307PubMed
8.
Zurück zum Zitat Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000 May 25; 405 (6785): 421–4PubMedCrossRef Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000 May 25; 405 (6785): 421–4PubMedCrossRef
9.
Zurück zum Zitat Barak Y, Liao D, He W, et al. Effects of peroxisome proliferator-activated receptor delta? on placentation, adiposity, ?and colorectal ?cancer. Proc Natl Acad Sci U S A 2002 Jan 8; 99 (1): 303–8PubMedCrossRef Barak Y, Liao D, He W, et al. Effects of peroxisome proliferator-activated receptor delta? on placentation, adiposity, ?and colorectal ?cancer. Proc Natl Acad Sci U S A 2002 Jan 8; 99 (1): 303–8PubMedCrossRef
10.
Zurück zum Zitat Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated? receptors (PPARs): ?tissue distribution of PPAR-alpha, ?-beta, and -gamma in the adult rat. Endocrinology 1996 Jan; 137 (1): 354–66PubMedCrossRef Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated? receptors (PPARs): ?tissue distribution of PPAR-alpha, ?-beta, and -gamma in the adult rat. Endocrinology 1996 Jan; 137 (1): 354–66PubMedCrossRef
11.
Zurück zum Zitat Saluja I, Granneman JG, Skoff RP. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001 Mar 1; 33 (3): 191–204PubMedCrossRef Saluja I, Granneman JG, Skoff RP. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001 Mar 1; 33 (3): 191–204PubMedCrossRef
12.
Zurück zum Zitat Oliver Jr WR, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001 Apr 24; 98 (9): 5306–11PubMedCrossRef Oliver Jr WR, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001 Apr 24; 98 (9): 5306–11PubMedCrossRef
13.
Zurück zum Zitat He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999 Oct 29; 99 (3): 335–45PubMedCrossRef He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999 Oct 29; 99 (3): 335–45PubMedCrossRef
14.
Zurück zum Zitat Lim H, Gupta RA, Ma WG, et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999 Jun 15; 13 (12): 1561–74PubMedCrossRef Lim H, Gupta RA, Ma WG, et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999 Jun 15; 13 (12): 1561–74PubMedCrossRef
15.
Zurück zum Zitat Spellberg B. The cutaneous citadel: a holistic view of skin and immunity. Life Sci 2000 Jun 23; 67 (5): 477–502PubMedCrossRef Spellberg B. The cutaneous citadel: a holistic view of skin and immunity. Life Sci 2000 Jun 23; 67 (5): 477–502PubMedCrossRef
16.
Zurück zum Zitat Mansbridge JN, Knapp AM. Changes in keratinocyte maturation during wound healing. J Invest Dermatol 1987 Sep; 89 (3): 253–63PubMedCrossRef Mansbridge JN, Knapp AM. Changes in keratinocyte maturation during wound healing. J Invest Dermatol 1987 Sep; 89 (3): 253–63PubMedCrossRef
17.
Zurück zum Zitat Grose R, Werner S. An aPPARently protective mechanism for keratinocytes in wounded skin. Trends Mol Med 2002 Apr 1; 8 (4): 149–51PubMedCrossRef Grose R, Werner S. An aPPARently protective mechanism for keratinocytes in wounded skin. Trends Mol Med 2002 Apr 1; 8 (4): 149–51PubMedCrossRef
18.
Zurück zum Zitat Michalik L, Desvergne B, Tan NS, et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) alpha and PPAR beta mutant mice. J Cell Biol 2001 Aug 20; 154 (4): 799–814PubMedCrossRef Michalik L, Desvergne B, Tan NS, et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) alpha and PPAR beta mutant mice. J Cell Biol 2001 Aug 20; 154 (4): 799–814PubMedCrossRef
19.
Zurück zum Zitat Tan NS, Michalik L, Noy N, et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001 Dec 15; 15 (24): 3263–77PubMedCrossRef Tan NS, Michalik L, Noy N, et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001 Dec 15; 15 (24): 3263–77PubMedCrossRef
20.
Zurück zum Zitat Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol 2000 Jul; 20 (14): 5119–28PubMedCrossRef Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol 2000 Jul; 20 (14): 5119–28PubMedCrossRef
21.
Zurück zum Zitat Grose R, Hutter C, Bloch W, et al. A crucial role of beta1 integrins for keratinocyte migration in vitro and during cutaneous wound repair. Development 2002 May 1; 129 (9): 2303–15PubMed Grose R, Hutter C, Bloch W, et al. A crucial role of beta1 integrins for keratinocyte migration in vitro and during cutaneous wound repair. Development 2002 May 1; 129 (9): 2303–15PubMed
22.
Zurück zum Zitat Di-Poï N, Tan NS, Michalik L, et al. Anti-apoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002; 10 (4): 721–33PubMedCrossRef Di-Poï N, Tan NS, Michalik L, et al. Anti-apoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002; 10 (4): 721–33PubMedCrossRef
23.
Zurück zum Zitat Rivier M, Safonova I, Lebrun P, et al. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 1998 Dec; 111 (6): 1116–21PubMedCrossRef Rivier M, Safonova I, Lebrun P, et al. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 1998 Dec; 111 (6): 1116–21PubMedCrossRef
24.
Zurück zum Zitat Jaeckel EC, Raja S, Tan J, et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001 Oct; 127 (10): 1253–9PubMed Jaeckel EC, Raja S, Tan J, et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001 Oct; 127 (10): 1253–9PubMed
25.
Zurück zum Zitat Tong BJ, Tan J, Tajeda L, et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000 Nov-Dec; 2 (6): 483–90PubMedCrossRef Tong BJ, Tan J, Tajeda L, et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000 Nov-Dec; 2 (6): 483–90PubMedCrossRef
26.
Zurück zum Zitat Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 2000 Nov 21; 97 (24): 13275–80PubMedCrossRef Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 2000 Nov 21; 97 (24): 13275–80PubMedCrossRef
27.
Zurück zum Zitat Segawa Y, Yoshimura R, Hase T, et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002 May 1; 51 (2): 108–16PubMedCrossRef Segawa Y, Yoshimura R, Hase T, et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002 May 1; 51 (2): 108–16PubMedCrossRef
28.
Zurück zum Zitat Shao J, Sheng H, DuBois RN. Peroxisome-proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002 Jun 1; 62 (11): 3282–8PubMed Shao J, Sheng H, DuBois RN. Peroxisome-proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002 Jun 1; 62 (11): 3282–8PubMed
29.
Zurück zum Zitat Kersten S. Peroxisome proliferator activated receptor and obesity. Eur J Pharmacol 2002 Apr 12; 440 (2–3): 223–34PubMedCrossRef Kersten S. Peroxisome proliferator activated receptor and obesity. Eur J Pharmacol 2002 Apr 12; 440 (2–3): 223–34PubMedCrossRef
30.
Zurück zum Zitat Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998 Sep 10; 395 (6698): 137–43PubMedCrossRef Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998 Sep 10; 395 (6698): 137–43PubMedCrossRef
31.
Zurück zum Zitat Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999 Mar; 3 (3): 397–403PubMedCrossRef Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999 Mar; 3 (3): 397–403PubMedCrossRef
32.
Zurück zum Zitat Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995 Dec 1; 83 (5): 813–9PubMedCrossRef Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995 Dec 1; 83 (5): 813–9PubMedCrossRef
33.
Zurück zum Zitat Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997 Apr 29; 94 (9): 4312–7PubMedCrossRef Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997 Apr 29; 94 (9): 4312–7PubMedCrossRef
34.
Zurück zum Zitat Krey G, Braissant O, L’Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997 Jun; 11 (6): 779–91PubMedCrossRef Krey G, Braissant O, L’Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997 Jun; 11 (6): 779–91PubMedCrossRef
35.
Zurück zum Zitat Lim H, Dey SK. Minireview: a novel protascyclin sigaling- hanging out with nuclear receptors. Endocrinology 2002 Sep; 143 (9): 3207–10PubMedCrossRef Lim H, Dey SK. Minireview: a novel protascyclin sigaling- hanging out with nuclear receptors. Endocrinology 2002 Sep; 143 (9): 3207–10PubMedCrossRef
36.
Zurück zum Zitat Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPAR delta alters lipid metabolism in db/db mice. FEBS Lett. 2000 May 19; 473 (3): 333–6PubMedCrossRef Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPAR delta alters lipid metabolism in db/db mice. FEBS Lett. 2000 May 19; 473 (3): 333–6PubMedCrossRef
37.
Zurück zum Zitat Rosenfield RL, Kentsis A, Deplewski D, et al. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 1999 Feb; 112 (2): 226–32PubMedCrossRef Rosenfield RL, Kentsis A, Deplewski D, et al. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 1999 Feb; 112 (2): 226–32PubMedCrossRef
38.
Zurück zum Zitat Berger J, Leibowitz MD, Doebber TW, et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 1999 Mar 5; 274 (10): 6718–25PubMedCrossRef Berger J, Leibowitz MD, Doebber TW, et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 1999 Mar 5; 274 (10): 6718–25PubMedCrossRef
39.
Zurück zum Zitat Camp HS, Chaudhry A, Leff T. A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology 2001 Jul; 142 (7): 3207–13PubMedCrossRef Camp HS, Chaudhry A, Leff T. A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology 2001 Jul; 142 (7): 3207–13PubMedCrossRef
40.
Zurück zum Zitat Wright HM, Clish CB, Mikami T, et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000 Jan 21; 275 (3): 1873–7PubMedCrossRef Wright HM, Clish CB, Mikami T, et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000 Jan 21; 275 (3): 1873–7PubMedCrossRef
41.
Zurück zum Zitat Rieusset J, Touri F, Michalik L, et al. A new selective PPARγ antagonist with anti-obesity and anti-diabetic activity. Mol Endocrinol 2002; 16 (11): 2628–44PubMedCrossRef Rieusset J, Touri F, Michalik L, et al. A new selective PPARγ antagonist with anti-obesity and anti-diabetic activity. Mol Endocrinol 2002; 16 (11): 2628–44PubMedCrossRef
42.
Zurück zum Zitat Xu HE, Stanley TB, Montana VG, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002 Feb 14; 415 (6873): 813–7PubMedCrossRef Xu HE, Stanley TB, Montana VG, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002 Feb 14; 415 (6873): 813–7PubMedCrossRef
43.
Zurück zum Zitat Kuruvilla FG, Shamji AF, Sternson SM, et al. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 2002 Apr 11; 416 (6881): 653–7PubMedCrossRef Kuruvilla FG, Shamji AF, Sternson SM, et al. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 2002 Apr 11; 416 (6881): 653–7PubMedCrossRef
44.
Zurück zum Zitat Ashcroft GS, Yang X, Glick AB, et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999 Sep; 1 (5): 260–6PubMedCrossRef Ashcroft GS, Yang X, Glick AB, et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999 Sep; 1 (5): 260–6PubMedCrossRef
45.
46.
Zurück zum Zitat Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000 May; 136 (5): 609–16PubMedCrossRef Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000 May; 136 (5): 609–16PubMedCrossRef
47.
Zurück zum Zitat Chawla A, Barak Y, Nagy L, et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001 Jan; 7 (1): 48–52PubMedCrossRef Chawla A, Barak Y, Nagy L, et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001 Jan; 7 (1): 48–52PubMedCrossRef
Metadaten
Titel
Peroxisome Proliferator-Activated Receptor (PPAR)-β as a Target for Wound Healing Drugs
What is Possible?
verfasst von
Nguan Soon Tan
Liliane Michalik
Beatrice Desvergne
Professor Walter Wahli
Publikationsdatum
01.08.2003
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 8/2003
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200304080-00001

Weitere Artikel der Ausgabe 8/2003

American Journal of Clinical Dermatology 8/2003 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.